Department of Physiatry, Hospital for Special Surgery, New York, New York, USA.
Department of Rehabilitation Medicine, Mount Sinai Hospital, New York, New York, USA.
PM R. 2021 Dec;13(12):1340-1349. doi: 10.1002/pmrj.12583. Epub 2021 Apr 28.
Tendinosis is a chronic degenerative condition. Current research suggests both percutaneous needle tenotomy (PNT) and leukocyte-rich platelet-rich plasma (LR-PRP) may be effective treatments for chronic tendinosis, but no studies have assessed the effectiveness of PNT alone versus PNT with intratendinous LR-PRP for multiple tendon types in a single study.
To assess the efficacy of PNT versus PNT + LR-PRP to treat chronic tendinosis.
Double-blind, randomized, controlled comparative treatment study.
Primary academic institution.
A convenience sample of 40 participants who had chronic tendinosis (rotator cuff, wrist extensor, wrist flexor, hip abductor, proximal hamstring, patellar, or Achilles) confirmed via ultrasound, failed conservative treatment, and did not have tendon tears, known coagulopathy, or systemic illnesses.
Participants were randomly assigned to PNT (n = 19) or PNT + LR-PRP (n = 21). Participants and outcomes assessors were blinded to treatment assignments. PNT was performed with 20-30 passes of a 22-gauge needle under ultrasound guidance, with 1% lidocaine given outside the tendon. LR-PRP was processed from whole blood (30-60 mL) and injected into the affected tendon using the same PNT technique.
Primary outcome was current numerical rating scale pain at 6 weeks. Secondary outcomes were average pain, function, general well-being, and sleep quality at 6, 52, and 104 weeks.
Baseline characteristics were similar between groups. Overall, there were no significant differences between groups over time for any of the outcomes (P > .05). Between-group analyses showed significantly lower current and average pain after PNT compared to PNT + LR-PRP at 6 weeks (estimated-mean [SE]: 3.1[0.4] vs. 4.6[0.6], P = .04; 3.4[0.4] vs. 4.9[0.5], P = .03) only. Adverse event rates were low (PNT-3.9%; PNT + LR-PRP-5.0%) and related primarily to postprocedural pain and inflammation.
Although pain scores were lower after PNT compared to PNT + LR-PRP at 6 weeks, there were no between-group differences in outcomes at 52 or 104 weeks.
肌腱病是一种慢性退行性疾病。目前的研究表明,经皮针刀切开术(PNT)和富含白细胞的富血小板血浆(LR-PRP)可能是治疗慢性肌腱病的有效方法,但尚无研究评估单独 PNT 与 PNT 联合肌腱内 LR-PRP 治疗多种肌腱类型的效果。
评估 PNT 与 PNT+LR-PRP 治疗慢性肌腱病的疗效。
双盲、随机、对照治疗研究。
主要学术机构。
40 名参与者,他们患有慢性肌腱病(肩袖、腕伸肌、腕屈肌、髋外展肌、近端腘绳肌、髌腱、跟腱或跟腱),通过超声检查确诊,经保守治疗失败,且无肌腱撕裂、已知凝血障碍或全身性疾病。
参与者被随机分配至 PNT(n=19)或 PNT+LR-PRP(n=21)组。参与者和结果评估者对治疗分配均不知情。在超声引导下,用 22 号针进行 20-30 次穿刺,在肌腱外给予 1%利多卡因。LR-PRP 从全血(30-60mL)中提取,并使用相同的 PNT 技术注入受累肌腱。
主要结局指标为 6 周时的当前数字评分量表疼痛。次要结局指标为 6、52 和 104 周时的平均疼痛、功能、总体健康状况和睡眠质量。
两组间基线特征相似。总体而言,两组间在任何结局指标上的差异均无统计学意义(P>.05)。组间分析显示,与 PNT+LR-PRP 相比,PNT 在 6 周时的当前和平均疼痛明显较低(估计均值[SE]:3.1[0.4] vs. 4.6[0.6],P=.04;3.4[0.4] vs. 4.9[0.5],P=.03)。不良事件发生率较低(PNT-3.9%;PNT+LR-PRP-5.0%),主要与术后疼痛和炎症有关。
尽管与 PNT+LR-PRP 相比,PNT 在 6 周时的疼痛评分较低,但在 52 或 104 周时两组间的结局无差异。